Skip to main content
. Author manuscript; available in PMC: 2018 Jan 30.
Published in final edited form as: Psychol Bull. 2015 Nov;141(6):1178–1204. doi: 10.1037/a0039729

Table 2.

Effect sizes, sample sizes, and moderator codes for each sample in the meta-analysis.

Paper d N AIB Eff Sev Sus OR DPP DP SE Delay %F IC SOC
Bagley & Low, 1992 .08 41 B Y Y N R PP N L 66 I E
Bang, 1994 −.11 223 AI N Y N R PP Y S 54 I
Beach, 1966 .38 28 I N Y N O PP Y L I E
Beck & Davis, 1978
 1: Low Interest −.05 31 A N Y N R PP N S 42 I
 2: High Interest 1.03 31 A N Y N R PP N S 42 I
Beck, 1984 .77 226 I N Y N O PP N S 47 I
Berkowitz, 1998
 1: Low Sensation-Seeking, Message Choice .02 48 AIB Y Y Y R PP N M 62 I E
 2: Low Sensation-Seeking, No Message Choice −.23 34 AIB Y Y Y R PP N M 62 I E
 3: High Sensation-Seeking, Message Choice .21 42 AIB Y Y Y R PP N M 62 I E
 4: High Sensation-Seeking, No Message Choice .01 48 AIB Y Y Y R PP N M 62 I E
Brouwers & Sorrentino, 1993 .25 149 IB Y Y Y O D Y S 69 I
Brown, 1979 1.81 38 A N Y N R PP N S 0 I L
Burnett, 1981 1.06 76 AI N Y N O PP N S I
Calantone & Warshaw, 1985 .96 180 B Y Y N O PP N S I
Carey, 1990 .00 118 I N Y N O PP Y S I
Chang et al., 1989 −.10 1425 B N Y N R PP N S I E
Cho & Salmon, 2006 .42 239 IB N Y Y R PP Y SEH S 61 I
Chu, 1966
 1: Low Efficacy .36 240 B N Y Y O PP Y M C
 2: Medium Efficacy .52 242 B Y Y Y O PP Y M C
 3: High Efficacy 1.71 231 B Y Y Y O PP Y M C
Cooper et al., 2014
 1: Appearance .09 98 I Y Y R PP N SEH S 65 I E
 2: Cancer −.33 98 I Y Y R PP Y SEH S 65 I E
Dabbs & Leventhal, 1966 .68 120 AIB Y Y Y O PP Y S I E
Dahl et al., 2003 .80 68 B N Y N R PP Y S I
Das et al., 2003
 1: Study 1, Weak Arguments, Low Vulnerability -1.09 52 A Y Y N O PP N S I
 2: Study 1, Weak Arguments, High Vulnerability 1.39 37 A Y Y N O PP N S I
 3: Study 1, Strong Arguments, Low Vulnerability 2.12 45 A Y Y N O PP N S I
 4: Study 1, Strong Arguments, High Vulnerability −.63 43 A Y Y N O PP N S I
 5: Study 2, Weak Arguments, Low Vulnerability −.33 28 A Y Y N O PP N S I
 6: Study 2, Weak Arguments, High Vulnerability .11 28 A Y Y N O PP N S I
 7: Study 2, Strong Arguments, Low Vulnerability −.26 23 A Y Y N O PP N S I
 8: Study 2, Strong Arguments, High Vulnerability .23 32 A Y Y N O PP N S I
 9: Study 3, Weak Arguments −.50 31 AB Y Y Y O PP N S I
 10: Study 3, Strong Arguments .99 29 AB Y Y Y O PP N S I
de Hoog et al., 2005 .59 118 AIB Y Y Y O PP N S 69 I
de Hoog et al., 2008
 1: Study 1, Low Source Credibility .41 30 AI N Y Y O D N S 71 I
 2: Study 1, High Source Credibility .25 30 AI N Y Y O D N S 71 I
 3: Study 2, Weak Arguments .51 32 AI N Y Y O D N S 75 I
 4: Study 2, Strong Arguments .65 32 AI N Y Y O D N S 75 I
Dembroski et al., 1978
 1: Black Communicator .22 40 A Y Y Y R PP N 52 I E
 2: White Communicator 1.48 40 A Y Y Y R PP N 52 I E
Dijkstra & Bos, 2015 −.01 118 IB Y Y N R PP Y L 56 I E
Duke et al., 2014
 1: Threat vs. Control .41 1540 IB N Y N R PP N L 53 I E
 2: Threat + SE vs. SE .67 970 IB Y Y N R PP N L 53 I E
Evans et al., 1968 −.53 49 B N Y N R PP N M I E
Evans et al., 1970 .35 156 IB Y Y N R PP N M I E
Feenstra et al., 2014 .32 1128 AIB N Y N R PP N L 52 I E
France et al., 2014
 1: Threat vs. Control .65 141 I N Y N R PP N S 100 I E
 2: Threat + SE vs. SE .48 213 I Y Y N R PP N S 100 I E
Frandsen, 1963 .13 1080 A N Y N R PP N S I
Fukada, 1973 .30 345 IB Y Y N O D N S 57 C
Fukada, 1975
 1: Low Efficacy, Low Source Credibility −.19 76 AIB N Y Y O D N S 100 C
 2: Low Efficacy, High Source Credibility .58 76 AIB N Y Y O D N S 100 C
 3: High Efficacy, Low Source Credibility .31 76 AIB Y Y Y O D N S 100 C
 4: High Efficacy, High Source Credibility .89 76 AIB Y Y Y O D N S 100 C
Fukada, 1983a .94 48 AIB N Y N O D N L 100 C
Fukada, 1983 (2)
 1: No Forewarnings .99 76 I N Y Y O D N S 100 C
 2: Topic Content Forewarning .72 76 I N Y Y O D N S 100 C
 3: Persuasive Intent Forewarning .58 76 I N Y Y O D N S 100 C
 4: Fear Arousal Forewarning 1.08 76 I N Y Y O D N S 100 C
 5: Topic Content & Fear Arousal Forewarnings .94 76 I N Y Y O D N S 100 C
 6: Topic Content & Persuasive Intent Forewarnings 1.10 76 I N Y Y O D N S 100 C
 7: Persuasive Intent & Fear Arousal Forewarnings .64 76 I N Y Y O D N S 100 C
 8: All Three Forewarnings .55 76 I N Y Y O D N S 100 C
Fukada, 1988
 1: Receive Counterargument .86 42 I N Y N O D N S 100 C
 2: Don’t Receive Counterargument .4 42 I N Y N O D N S 100 C
Fukada, 1991 −.18 30 A N N N R PP N M 100 C
Gleicher & Petty, 1992 .23 336 A Y Y Y R PP N I
Goldenbeld et al., 2008
 1: Males −.05 42 AI Y Y N R PP Y S 0 I
 2: Females .73 32 AI Y Y N R PP Y S 100 I
Griffeth & Rogers, 1976 1.17 137 IB Y Y N R PP Y SEE S I
Hass et al., 1975 .60 56 I N Y N R PP N S I
Hendrick et al., 1975
 1: Study 1, Fear Reduction .15 40 AI N N N O PP N S 100 I
 2: Study 1, No Fear Reduction .72 40 AI N N N O PP N S 100 I
 3: Study 2 .24 122 AI N N N O PP N S 100 I
Hill & Gardner, 1980
 1: Repressors −.59 27 B N Y N O D N S 0 I
 2: Sensitizers .44 25 B N Y N O D N S 0 I
Hoeken & Geurts, 2005 −.34 149 I N Y N R PP N S 83 I
Horowitz & Gumenik, 1970 .26 112 A N Y N R PP Y S I
Horowitz, 1969
 1: Single Exposure .37 60 A N Y N R PP Y S 0 I
 2: Multiple Exposures .10 60 A N Y N R PP Y M 0 I
Insko et al., 1965
 1: Males .00 72 AI N Y Y R PP N SEE S 0 I
 2: Females .00 72 AI N Y Y R PP N SEE S 100 I
Janis & Feshbach, 1954
 1: Low Anxiety −.14 80 AB N Y N R PP N M I
 2: High Anxiety −.68 51 AB N Y N R PP N M I
Janis & Terwilliger, 1962 −.72 31 A N Y N R PP Y S 19 I
Janssens & De Pelsmacker, 2007
 1: Non-Drivers −.04 95 A N Y N R PP Y SEE S I
 2: Drivers .01 89 A N Y N R PP Y S I
Johnston, 2006
 1: No Pre-Test .57 60 A Y Y Y O PP N S 38 I E
 2: Pre-Test .58 60 A Y Y Y O PP N S 38 I E
Jones & Owen, 2006
 1: Ages 18–39 .00 44 I Y Y N R D N S 100 I E
 2: Ages 40–49 .00 44 I Y Y N R D N S 100 I E
 3: Ages 50+ −.19 61 I Y Y N R D N S 100 I L
Kareklas & Muehling, 2014
 1: No Verbal, Control vs. Visual .25 112 AI N Y N R PP Y S 44 I E
 2: Verbal, Control vs. Visual .10 112 AI N Y N R PP Y S 44 I E
Keller & Block, 1996
 1: Self-Reference −.01 51 I Y Y Y R PP Y S I E
 2: Other-Reference .84 47 I Y Y N R PP Y S I E
Keller, 1999
 1: Don’t Use Condoms −.68 27 I Y Y N R PP Y S 100 I E
 2: Regularly Use Condoms .66 34 I Y Y N R PP Y SEE S 100 I L
Kim et al., 2009 .00 183 B N N N R PP N L 53 C
Kirscht & Haefner, 1973
 1: One Exposure .22 30 B N N N R PP N L 58 I
 2: Two Exposures .06 28 B N N N R PP Y L 58 I
 3: Three Exposures −.10 27 B N N N R PP Y L 58 I
Kirscht et al., 1978 1.23 109 B N Y N R PP Y SEE M 100 I E
Kleinot & Rogers, 1982
 1: Low Efficacy .77 22 I N Y Y R PP Y S I E
 2: High Efficacy 1.16 22 I Y Y Y R PP Y S I E
Klohn & Rogers, 1991 .68 85 I N Y N R PP N SEE S 100 I E
LaTour et al., 1996 .29 305 AI N Y N O PP N S 100 I
LaTour & Tanner, 2003 .13 124 AI N Y N O D N S 43 I
Leventhal & Niles, 1964 .45 209 AI Y Y N O D N S I E
Leventhal & Watts, 1966
 1: Smokers −1.57 52 B Y Y N O D N S I E
 2: Non-Smokers −.02 48 B Y Y N O D N SEE S I
Leventhal et al., 1965
 1: No Prior Vaccination .60 59 AI Y Y Y O PP N S I E
 2: Prior Vaccination .36 88 AI Y Y Y O PP N S I L
Leventhal et al., 1967 .53 106 I Y Y N R PP N S I E
Levin et al., 2007 −.41 222 I N Y N R PP N S I E
Lewis et al., 2008
 1: Male, Low Involvement .23 35 A N Y N R PP Y SEE L 0 I L
 2: Male, High Involvement .44 36 A N Y N R PP Y L 0 I E
 3: Female, Low Involvement .91 65 A N Y N R PP Y SEE L 100 I L
 4: Female, High Involvement .87 65 A N Y N R PP Y L 100 I E
Lewis et al., 2010 −.08 270 I N N N R PP N S 66 I
Li, 2002
 1: Low Outcome .27 28 AI N Y Y O D N S 44 I E
 2: High Outcome .45 29 AI Y Y Y O D N S 44 I E
Liberman & Chaiken, 1992
 1: Low Relevance .35 86 I N N Y R PP N S 100 I
 2: High Relevance .35 86 I N N Y R PP N SEE S 100 I
Lwin & Malik, 2014
 1: With Wii .10 199 AI N Y N R PP N SEE L 42 C E
 2: Without Wii −.24 199 AI N Y N R PP N SEE L 42 C E
McMath & Prentice-Dunn, 2005 1.06 196 I Y Y N R PP N SEH S 74 I E
Meijnders et al., 2001a
 1: Weak Arguments −.27 54 AI N Y N O PP N S 50 I
 2: Strong Arguments .47 54 AI N Y N O PP N S 50 I
Meijnders et al., 2001b
 1: Weak Arguments .46 40 A Y Y N O PP N S 67 I
 2: Strong Arguments .47 40 A Y Y N O PP N S 67 I
Morales et al., 2012
 1: Study 1 (Methamphetamine Use) .42 104 I N N N R PP Y S I
 2: Study 2 (Sun Safety) .43 94 I N N N R PP N SEH S I
 3: Study 3 (BPA Products) −.20 54 I N Y N O PP S I
Morris et al., 2014
 1: Study 1, UV Photo .31 31 IB N Y Y R PP Y SEH S 100 I E
 2: Study 1, No UV Photo −.53 28 IB N Y N R PP Y SEH S 100 I E
 3: Study 2, Appearance Focus 1.05 24 I N N Y R PP Y SEH S 100 I E
 4: Study 2, Health Focus −.30 27 I N N Y R PP Y SEH S 100 I E
 5: Study 2, No Photo −.51 33 I N N N R PP Y SEH S 100 I E
Muthusamy et al., 2009
 1: No Efficacy Message −.20 124 AIB N Y Y R PP N M 68 C E
 2: Efficacy Message .08 124 AIB Y Y Y R PP N M 68 C E
Ordoñana et al., 2009
 1: No Efficacy Message .59 45 IB N Y Y O PP N L 83 I E
 2: Efficacy Message .52 47 IB Y Y Y O PP N L 83 I E
Pengchit, 2010 1.25 124 B Y Y Y O PP N S I
Pepper & Nettle, 2014
 1: Study 1 −.22 72 IB N R PP Y SEE S 46 I E
 2: Study 2 .14 66 IB N N Y R PP Y SEE S 40 I E
Powell, 1965
 1: Threat to Listener −.52 28 A N N N O PP Y S 0 I
 2: Threat to Family .84 28 A N N N O PP Y S 0 I
 3: Threat to Nation .01 24 A N N N O PP Y S 0 I
Priolo & Milhabet, 2008
 1: Study 1, Smokers Committed to Quitting .72 60 I N R PP Y SEE S 85 I E
 2: Study 1, Smokers Not Committed to Quitting −.16 60 I N R PP Y SEH S 85 I E
 3: Study 2, Smokers Committed to Smoking −.55 60 I N R PP Y SEH S 85 I E
 4: Study 2, Smokers Not Committed to Smoking .49 60 I N R PP Y SEE S 85 I E
Radelfinger, 1965 .90 131 I Y Y N O PP N S I E
Raleigh, 2002
 1: Males, Low Response Costs −.19 17 I Y N Y R PP N S 0 I E
 2: Males, High Response Costs −.25 13 I N N Y R PP N S 0 I E
 3: Females, Low Response Costs −.24 11 I Y N Y R PP N S 100 I E
 4: Females, High Response Costs −.78 10 I N N Y R PP N S 100 I E
Ramirez & Lasater, 1976 .00 462 B Y Y N R PP N S I E
Ramirez & Lasater, 1977 .30 196 B Y Y N R PP N S I E
Rippetoe & Rogers, 1987 .69 128 I Y Y Y R D N S 100 I E
Rodriguez, 1995
 1: Bicycle Safety .98 124 A N Y N R PP Y S I E
 2: Drinking .54 125 A N N Y R PP Y S I E
 3: Tetanus Vaccine .42 120 A N Y Y O PP N S I
Rogers & Deckner, 1975
 1: Study 1 .25 116 AIB N Y N R PP N S I E
 2: Study 2 .38 152 AI Y Y N R PP N S I E
Rogers & Mewborn, 1976
 1: Low Efficacy −.04 44 I Y Y Y R PP N S I
 2: High Efficacy .41 44 I N Y Y R PP N S I
Rogers & Thistlethwaite, 1970
 1: Smokers .47 40 I Y Y N R PP N S I E
 2: Non-Smokers .82 40 I Y Y N R PP N SEE S I
Rosen et al., 1982
 1: Low Self-Esteem .14 28 I N Y Y O PP Y S 49 I E
 2: High Self-Esteem −.24 28 I N Y Y O PP Y S 49 I E
Rosenthal, 1997
 1: Peptic Ulcers .01 70 AI N N Y O PP N S I
 2: Heart Disease .26 70 AI N N Y O PP N S I
Roskos-Ewoldsen et al., 2004
 1: Low Efficacy −.19 55 AI N N Y R D Y S 100 I
 2: High Efficacy .10 55 AI Y N Y R D Y S 100 I
Ruiter et al., 2003 .17 130 AI N Y Y R D Y S 100 I
Schmitt & Blass, 2008 .56 30 AI N Y N R PP Y SEE S I
Schoenbachler & Whittler, 1996 .00 248 AI N Y N R PP Y S I
Self & Rogers, 1990
 1: Low Efficacy −.55 42 I N Y Y R PP N S 55 I
 2: High Efficacy .64 42 I Y Y Y R PP N S 55 I
Shehryar & Hunt, 2005
 1: Study 1, Low Commitment to Drunk Driving .01 45 A N Y N R PP Y SEE S 57 I
 2: Study 1, High Commitment to Drunk Driving -1.07 45 A N Y N R PP Y SEH S 57 I
 3: Study 2, Low Commitment to Drunk Driving, No Delay −.79 25 A N Y N R PP Y SEE S 57 I
 4: Study 2, High Commitment to Drunk Driving, No Delay .12 25 A N Y N R PP Y SEH S 57 I
 5: Study 2, High Commitment to Drunk Driving, Delay −1.17 25 A N Y N R PP Y SEH S 57 I
Shelton & Rogers, 1981
 1: Low Empathy .85 56 I Y Y N R PP N S I
 2: High Empathy .26 56 I Y Y N R PP N S I
Shen, 2011 .59 174 A N Y N R PP N S 66 I L
Siero et al., 1984 .24 269 B N Y Y R D Y L 100 I L
Skilbeck et al., 1977
 1: Single Exposure −.99 40 B N Y N R PP N SEE M 100 I E
 2: Multiple Exposures −1.23 46 B N Y N R PP N SEE M 100 I E
Smalec & Klingle, 2000
 1: Low Efficacy −.60 22 B N Y Y O PP N SEH S 81 I L
 2: High Efficacy 1.40 22 B Y Y Y O PP N SEH S 81 I L
Smart & Fejer, 1974
 1: Marijuana, Non-Users −.05 856 I N Y Y R PP N SEE S I
 2: Marijuana, Users −.17 249 I N Y Y R PP N S I E
 3: Fictional Drug 1.66 194 I N Y Y R PP N S I
Smerecnik & Ruiter, 2010
 1: Low Efficacy −.19 30 I N Y N R PP Y S 65 I L
 2: High Efficacy .76 30 I Y Y N R PP Y S 65 I L
Smith & Stutts, 2003
 1: Males, Overall .29 79 B N Y N R PP Y L 0 I
 2: Females, Overall .38 76 B N Y N R PP Y L 100 I
 3: White Subjects .51 61 B N Y N R PP Y L 49 I
 4: Hispanic Subjects .29 55 B N Y N R PP Y L 49 I
 5: African-American Subjects .41 24 B N Y N R PP Y L 49 I
Stainback & Rogers, 1983
 1: Immediate Post-Test .65 38 I Y Y Y R PP N SEE S I
 2: Delayed Post-Test 1.30 38 I Y Y Y R PP N SEE S I
Stark et al., 2008
 1: Lozenges .24 90 AI N Y N R PP N S 73 I E
 2: Reduced-Exposure Cigarettes .42 90 AI N Y N R PP N S 73 I E
 3: Oral Tobacco .34 90 AI N Y N R PP N S 73 I E
Stephenson & Witte, 1998 .47 92 AI Y Y N R PP N SEH S 56 I E
Struckman-Johnson et al., 1990
 1: Males −.10 96 I N R PP N S 0 I
 2: Females −.03 95 I N R PP N S 100 I
Sturges & Rogers, 1996
 1: Kids, Low Coping .02 30 I N Y Y R PP N SEE S 50 I
 2: Kids, High Coping .43 37 I Y Y Y R PP N SEE S 50 I
 3: Teens, Low Coping .05 23 I N Y Y R PP N SEE S 50 I
 4: Teens, High Coping .32 22 I Y Y Y R PP N SEE S 50 I
 5: Adults, Low Coping −.34 31 I N Y Y R PP N SEE S 50 I
 6: Adults, High Coping .27 38 I Y Y Y R PP N SEE S 50 I
Tanner et al., 1991 .81 60 I N R PP N S I
Taubman Ben-Ari et al., 2000
 1: Study 1, Low Driving-Related Self-Esteem 1.06 27 I N Y N R PP Y SEE S 0 C
 2: Study 1, High Driving-Related Self-Esteem .08 27 I N Y N R PP Y SEH S 0 C
 3: Study 2, Low Driving-Related Self-Esteem −.76 27 B N Y N R PP Y SEE S 0 C
 4: Study 2, High Driving-Related Self-Esteem .20 28 B N Y N R PP Y SEH S 0 C
ter Horst et al., 1985 −.12 107 B Y Y Y O PP N S I E
Thornton et al., 2000 −.65 112 I N Y N R PP N S I L
Umeh & Stanley, 2005 −.04 100 I Y Y N R PP N S 0 I
Umeh, 2012
 1: Low Credibility Source .06 134 I Y Y N R D Y S 100 I
 2: High Credibility Source .25 134 I Y Y N R D Y S 100 I
Venkatesan, 2010 3.01 72 A Y N Y O PP N L 100 I E
Weinstein et al., 1990 .24 264 I Y Y Y O D Y S I
Welbourne et al., 2008 .00 308 A N Y N R PP Y S I
Wheatley & Oshikawa, 1970
 1: Low Anxiety .30 49 A N N N O PP Y S I
 2: High Anxiety −.14 47 A N N N O PP Y S I
Will et al., 2009 .54 352 AB Y Y N O PP N S 80 I E
Witte & Morrison, 1995 −.32 122 AIB Y Y Y R PP N L 45 I
Witte et al., 1998 .03 96 AIB N Y Y R PP N S 100 I
Wong & Cappella, 2009
 1: Low Efficacy −.01 277 I N Y N R PP Y S 47 I E
 1: High Efficacy .81 278 I Y Y N R PP Y S 47 I E
Wurtele & Maddux, 1987
 1: No Efficacy Message 1.42 40 I N N Y R PP N SEE M 100 I E
 2: Self-Efficacy Message −.11 40 I Y N Y R PP N SEE M 100 I E
 3: Response-Efficacy Message .75 40 I Y N Y R PP N SEE M 100 I E
 4: Both Efficacy Messages 1.22 40 I Y N Y R PP N SEE M 100 I E
Wurtele, 1988 .82 49 IB Y N Y R PP N M 100 I E
Yoon & Tinkman, 2013
 1: Low Past Threat, Nonhumor Ads −.28 48 AI N Y N R PP Y SEH S I E
 2: Low Past Threat, Humor Ads .60 48 AI N Y N R PP Y SEH S I E
 3: High Past Threat, Nonhumor Ads .62 48 AI N Y N R PP Y SEH S I E
 4: High Past Threat, Humor Ads −.58 48 AI N Y N R PP Y SEH S I E

Note: d = Standardized mean effect size. N = Sample size for treatment plus comparison. AIB = Whether d was based on attitude (A), intention (I), and/or behavior (B) outcomes. EFF = Whether an efficacy statement was included (Y) or not (N). Sev = Whether the treatment message was manipulated to be higher in depicted severity than the comparison message (Y) or not (N). Sus = Whether the treatment message was manipulated to be higher in depicted susceptibility than the comparison message (Y) or not (N). OR = Whether the recommended behavior was one-time (O) or repeated (R). DPP = Whether the recommended behavior was detection (D) or prevention/promotion (PP). DP = Whether the word death was present in the message (Y) or not (N). SE = Whether the recommended behavior was self-esteem enhancing (SEE) or self-esteem hindering (SEH). Delay = Whether the outcome followed exposure to the message by less than 24 hours (S), 1–14 days (M), or more than 14 days (L). %F = Percent of sample that was female (0–100%). IC = Whether the sample was from an individualist (I) or collectivist (C) culture. SOC = Whether the sample was in the early (E) or late (L) stages of change. Dash (–) indicates the variable was not relevant for the study.